Related coverage linked through entity extraction aliases.
Jun 19, 2026
CO-005, a humanized anti-CD47 fusion protein from Caedo Oncology, showed potent antitumor activity in preclinical models of B-cell lymphoma, including rituximab-resistant tumors. The therapy induces programmed cancer cell death while disrupting immune checkpoints, offering a potential solution to CD20 resistance.
Feb 16, 2026
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
Feb 13, 2026
The U.S. FDA granted orphan drug designation to HCB101, a next-generation immunotherapy from HanchorBio, for treating gastric cancer including HER2-positive and HER2-negative subtypes.
